MUMBAI, India, March 13 -- Intellectual Property India has published a patent application (202641024541 A) filed by Mavurapu Satyanarayana; Archana Garipally; Shireesha Boyapati; Chelimela Narsaiah; Nimma Rameshwar; Menga Prasanna Sheela; and Rajasekhar Reddy Alavala, Hyderabad, Telangana, on March 2, for 'o-linked 4,6-disubstituted pyrimidine-1,2,3-triazole hybrid compounds, process for their preparation and antiproliferative use thereof.'
Inventor(s) include Mavurapu Satyanarayana; Archana Garipally; Shireesha Boyapati; Chelimela Narsaiah; Nimma Rameshwar; Menga Prasanna Sheela; and Rajasekhar Reddy Alavala.
The application for the patent was published on March 13, under issue no. 11/2026.
According to the abstract released by the Intellectual Property India: "A series of novel hybrids of 4,6-diphenyl pyrimidine-triazole were designed, synthesized, and systematically evaluated for their anticancer potential. The proposed compounds were efficiently synthesized via O-propargylation of 4,6-diphenylpyrimidin-2(1H)-one followed by azide-alkyne cycloaddition catalysed by Cu(I) (click chemistry) to form distinct class of triazole-linked hybrids (9a-9e). All the synthesized compounds were characterized using IR, 1H/13C-NMR, and HRMS spectra. The antiproliferative activity of the compounds (9a-9e) was evaluated against human breast (MCF-7) and lung (A549) cancer cell lines, along with safety evaluation on human fibroblast cells (NIH). These derivatives showed moderate to good antiproliferative activity with negligible toxicity towards normal cells. Particularly, compound 9c showed promising cytotoxicity in MCF-7 and 9d and 9e in A549 cell lines, respectively. Overall, the integrated synthetic and biological examination highlights the hybrids of pyrimidine-triazoles as structurally robust scaffolds with promising antiproliferative activity."
Disclaimer: Curated by HT Syndication.
